Lung cancer is usually a neglected entity in the universe of cancer management in India. It is not one of the first diagnosis in the mind of the primary doctors, neither is it one of the top priorities in the cancer treatment centres. Even when we talk about awareness we restrict ourselves to Breast and Gynaecological cancers and sometimes to head and neck cancers for males but conveniently forget lung cancers. One of the main reasons for this step motherly treatment of lung cancer is usually the dismal prognosis associated with it. Once the diagnosis of lung cancer is confirmed, everybody, including the treating doctors, condemn the patient to a life span of under a year and feel that there is not much point treating such patients.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
